These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8940206)

  • 1. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.
    Putnak R; Barvir DA; Burrous JM; Dubois DR; D'Andrea VM; Hoke CH; Sadoff JC; Eckels KH
    J Infect Dis; 1996 Dec; 174(6):1176-84. PubMed ID: 8940206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells.
    Putnak R; Cassidy K; Conforti N; Lee R; Sollazzo D; Truong T; Ing E; Dubois D; Sparkuhl J; Gastle W; Hoke C
    Am J Trop Med Hyg; 1996 Nov; 55(5):504-10. PubMed ID: 8940981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.
    Fernandez S; Thomas SJ; De La Barrera R; Im-Erbsin R; Jarman RG; Baras B; Toussaint JF; Mossman S; Innis BL; Schmidt A; Malice MP; Festraets P; Warter L; Putnak JR; Eckels KH
    Am J Trop Med Hyg; 2015 Apr; 92(4):698-708. PubMed ID: 25646261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.
    Imoto J; Konishi E
    Vaccine; 2007 Jan; 25(6):1076-84. PubMed ID: 17084490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
    Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
    Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
    Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
    Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
    Putnak R; Fuller J; VanderZanden L; Innis BL; Vaughn DW
    Am J Trop Med Hyg; 2003 Apr; 68(4):469-76. PubMed ID: 12875299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on a purified and inactivated Japanese encephalitis vaccine prepared on Vero cells using SA14-14-2 attenuated virus strain].
    Yao Z; Dong G; Yu Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Jun; 13(2):191-3. PubMed ID: 12569794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
    Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection.
    Eckels KH; Dubois DR; Summers PL; Schlesinger JJ; Shelly M; Cohen S; Zhang YM; Lai CJ; Kurane I; Rothman A
    Am J Trop Med Hyg; 1994 Apr; 50(4):472-8. PubMed ID: 8166355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
    Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
    BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
    Kraiselburd E; Kessler MJ; Torres-Blasini G
    Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells.
    Appaiahgari MB; Vrati S
    Vaccine; 2004 Sep; 22(27-28):3669-75. PubMed ID: 15315846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.